Serum Metabolomic Profiles for Breast Cancer Diagnosis, Grading and Staging by Gas Chromatography-Mass Spectrometry

Hadi, Naila Irum; Jamal, Qamar; Iqbal, Ayesha; Shaikh, Fouzia; Somroo, Saleem; Musharraf, Syed Ghulam

doi:10.1038/s41598-017-01924-9

Cited by 64 publications

(50 citation statements)

References 45 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amino sugar metabolism (hexosamine pathway) is also observed to be altered in the IDC tissue (Figure 4 ). These observations are in good agreement with a recent breast cancer metabolomics study by Hadi et al using GC-MS [ 42 ]. N-acetylgalactosamine (GalNAc) is an important component of glycoprotein as it is the first glycan added in the O-glycosylation process, initiation of which aids invasiveness [ 43 ].…”

Section: Discussionsupporting

confidence: 92%

“…An increase in the concentration of omega-6-polyunsaturated fatty acids (PUFAs) has been observed, which are important in modulating various physiological functions including initiation and sustainment of inflammation (Figure 4 ) [ 41 ]. Moreover, the increased fatty acid metabolism has also been reported to be associated with invasive breast cancer [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomic alterations in invasive ductal carcinoma of breast: A comprehensive metabolomic study using tissue and serum samples

RoyChoudhury

Christie

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Invasive ductal carcinoma (IDC) is the most common type of breast cancer and the leading cause of breast cancer related mortality. In the present study, metabolomic profiles of 72 tissue samples and 146 serum samples were analysed using targeted liquid chromatography multiple reaction monitoring mass spectrometry (LC-MRM/MS) and untargeted gas chromatography mass spectrometry (GC-MS) approaches. Combination of univariate and multivariate statistical treatment identified significant alterations of 42 and 32 metabolites in tissue and serum samples of IDC, respectively when compared to control. Some of the metabolite changes from tissue were also reflected in serum, indicating a bi-directional interaction of metabolites in IDC. Additionally, 8 tissue metabolites and 9 serum metabolites showed progressive change from control to benign to IDC suggesting their possible role in malignant transformation. We have identified a panel of three metabolites viz. tryptophan, tyrosine, and creatine in tissue and serum, which could be useful in screening of IDC subjects from both control and benign. The metabolomic alterations in IDC showed perturbations in purine and pyrimidine metabolism, amino sugar metabolism, amino acid metabolism, fatty acid biosynthesis etc. Comprehensively, this study provides valuable insights into metabolic adaptations of IDC, which can help to identify diagnostic markers as well as potential therapeutic targets.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Metabolomic alterations in invasive ductal carcinoma of breast: A comprehensive metabolomic study using tissue and serum samples

RoyChoudhury

Christie

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Metabolomics is considered as a relatively rapid, accurate and noninvasive method, it is becoming an increasingly popular tool in discovery of diagnostic biomarkers of cancers [ 209 , 210 ]. Many enthusiastic metabolomic markers have been reported for diagnosis and prognosis in lung cancer [ 205 , 208 , 211 ], breast cancer [ 204 , 212 ], pancreatic cancer [ 206 ], Pca [ 213 – 215 ], bladder cancer [ 216 – 218 ], and epithelial ovarian cancer [ 219 , 220 ].…”

Section: Methodology and Application Of Metabolomics In Cancer Researmentioning

confidence: 99%

The crucial role of multiomic approach in cancer research and clinically relevant outcomes

2018

View full text Add to dashboard Cite

Cancer with heavily economic and social burden is the hot point in the field of medical research. Some remarkable achievements have been made; however, the exact mechanisms of tumor initiation and development remain unclear. Cancer is a complex, whole-body disease that involves multiple abnormalities in the levels of DNA, RNA, protein, metabolite and medical imaging. Biological omics including genomics, transcriptomics, proteomics, metabolomics and radiomics aims to systematically understand carcinogenesis in different biological levels, which is driving the shift of cancer research paradigm from single parameter model to multi-parameter systematical model. The rapid development of various omics technologies is driving one to conveniently get multi-omics data, which accelerates predictive, preventive and personalized medicine (PPPM) practice allowing prediction of response with substantially increased accuracy, stratification of particular patients and eventual personalization of medicine. This review article describes the methodology, advances, and clinically relevant outcomes of different “omics” technologies in cancer research, and especially emphasizes the importance and scientific merit of integrating multi-omics in cancer research and clinically relevant outcomes.

show abstract

“…Incidence vary from 19.3 per 100,000 women in eastern Africa to 89.7 per 100,000 in western europe [22,23]. Some decrease in the number of death caused by BC is observed mainly due to the improvement in early diagnostics [24]. Nevertheless, routine methods currently used to detect BC usually are not effective, especially in the very early stages [25].…”

Section: Introductionmentioning

confidence: 99%

Is Metabolomics the Diagnostic Tool for Medical Diagnostics of Cancer? An Example Based on Lung and Breast Cancer

Lamasz¹,

Barg²,

Młynarz³

2018

IJMMR

View full text Add to dashboard Cite

Background. Metabolomics is a relatively new diagnostic tool that allows a deep insight into the body metabolism at a cellular level. Objective. This paper provides a comprehensive view into the metabolomic methodology and shows usefulness of this approach in diagnosing and stratifying lung and breast cancers. Methods. Literature review of metabolomics studies and its clinical application in the diagnosis of cancer-selected studies.Results. In general, the metabolomic approach comprises three steps: 1) sampling and preparing biofluids or tissue homogenates, 2) identification of low-molecular weight compounds up to 1.0 kDa using nuclear magnetic resonance, mostly 1H-NMR and/or mass spectrometry, and finally 3) data processing and analysing. It is possible to identify a set of metabolites which is specific for a certain metabolic status (the metabolic fingerprint). Furthermore, this set of metabolites provides information of possible pathomechanisms involved in the disease process i.e. information about the disease etiology. It has been proven that the change in metabolome precedes other biomarkers of the disease; not only clinical symptoms but other laboratory findings as well. Consequently, this approach, if sufficiently validated, seems to be very promising especially in screening and early diagnosing. Conclusions. It was demonstrated that metabolomic approach allows to discriminate patients with cancer from healthy persons, as well as to differentiate between clinical stages of the cancer.

show abstract

Serum Metabolomic Profiles for Breast Cancer Diagnosis, Grading and Staging by Gas Chromatography-Mass Spectrometry

Cited by 64 publications

References 45 publications

Metabolomic alterations in invasive ductal carcinoma of breast: A comprehensive metabolomic study using tissue and serum samples

Metabolomic alterations in invasive ductal carcinoma of breast: A comprehensive metabolomic study using tissue and serum samples

The crucial role of multiomic approach in cancer research and clinically relevant outcomes

Is Metabolomics the Diagnostic Tool for Medical Diagnostics of Cancer? An Example Based on Lung and Breast Cancer

Contact Info

Product

Resources

About